Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sorbent Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Formed by a cadre of veterans from Baxter Healthcare’s renal division, Sorbent Therapeutics Inc. is developing polymer drugs that treat disease through the management of sodium and fluid volume in the body. Those two factors, along with potassium reduction or retention depending upon the condition, are keys to addressing a string of related illnesses including end-stage renal disease and congestive heart failure. Sorbent’s polymer drugs remove sodium from the gastrointestinal tract but are not absorbed into the rest of the bloodstream, thereby minimizing any number of potential toxicity, bioavailability and metabolism risks.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts